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INTRODUCTION: Phyllodes tumours are rare ﬁbroepithelial malignancies of the breast, accounting for less
than 1% of malignant breast tumours. Further malignant differentiation of phyllodes tumours can occur,
resulting in cases of extremely rare heterologous sarcomatous differentiation.
PRESENTATION OF CASE: Two females in their ﬁfties were diagnosed with malignant phyllodes tumour
associated with heterologous sarcomatous differentiation. The ﬁrst patient, aged 50 had phyllodes
tumour with chondrosarcoma, osteosarcoma and ductal carcinoma-in-situ. The second patient, aged
53 had phyllodes tumour with osteosarcoma and liposarcoma.
DISCUSSION: The association of phyllodes tumour and heterologous sarcomatous differentiation is rare,
with only 4 previously reported cases in English literature. The paucity of evidence presents challenges in
itsmanagementwithuncertainprognosis andmonitoring requirements for twoaforementionedpatients.
CONCLUSION: Further case series and long-term follow up is required for accurate characterisation of
phyllodes tumours with heterologous sarcomatous differentiation.
Crown Copyright © 2015 Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Phyllodes tumours (PTs) are rare ﬁbroepithelial malignancies
of the breast and account for less than 1% of malignant breast
tumours [1,2]. They are fast growing tumours that originate from
peri-ductal stromaandare composedof both epithelial and stromal
components [3]. PTs can be classiﬁed by histopathological features
as benign, borderline or malignant, but all PTs have the potential
to become malignant although behaviourally is relatively poorly
predicted from histological appearances [4]
PTs areusually solitary tumoursbut canbeassociatedwithother
malignancies of the breast [5,6]. In particular, malignant differen-
tiation of both the epithelial and stromal components of PTs can
occurwith carcinomas, invasive and in situ, arising from the epithe-
lial component sarcomas such as chondrosarcomas, osteosarcomas
and liposarcomas, can be seen in associationwith the stromal com-
ponent of a PT [6]. PTs can also co-exist with a distinctly separate
malignant tumour inboth the ipsilateral and/or contralateral breast
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[3]. The association of PTs with heterologous sarcomatous differ-
entiation is a rare occurrencewith only 4 previously reported cases
in English literature [5–8].
We present 2 cases of malignant PTs associated with multiple
malignancies: the ﬁrst patient had PT with chondrosarcomatous
and osteosarcomatous differentiation and ductal carcinoma in situ
(DCIS) in the ipsilateral breast, with lobular carcinoma and DCIS in
the contralateral breast. The second patient had PT with osteosar-
comatous and liposarcomatous differentiation.
2. Case series
2.1. Case 1
A 50 year old female presented with a 2 year history of a large
palpable mass in her left breast. She had a sister who developed
breast cancer at 45 years of age but had no other risk factors. A
mammogram and ultrasound demonstrated a lesion of approxi-
mately 11 cm in the left breast, with a 10mm impalpable lesion in
her right breast (Fig. 1). Core biopsy of the left breast revealed a PT
and a core biopsy of the right breast demonstrated atypical lobular
neoplasia.
http://dx.doi.org/10.1016/j.ijscr.2015.02.009
2210-2612/Crown Copyright © 2015 Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Ultrasound imaging of right breast.
The patient underwent a left mastectomy and a hookwire
localised excision of the right breast lesion, with no operative com-
plications.
Pathology of the left mastectomy revealed a malignant PT char-
acterised by a classical ‘leaf-like’ growth pattern showing marked
stromal overgrowth containing malignant spindle cells with high
mitotic rate up to 34 mitotic ﬁgures in 10 high power ﬁelds.
Fig. 2. (H&E) phyllodes tumour with leaf-shaped formation of ductal-carcinoma in
situ.
Fig. 3. (H&E) phyllodes tumour with malignant osteosarcoma.
Within the PT, elements of chondrosarcoma, osteosarcoma and
DCIS (intermediate grade) were present. The DCIS was oestrogen
andprogesterone receptor positive. The pathology is demonstrated
in Fig. 2–4.
The right hookwire localised excision demonstrated invasive
lobular carcinoma (grade 1), which was oestrogen and pro-
gesterone receptor positive, HER2 negative. This excision was
complete with clear margins. There was also a focus of DCIS (inter-
mediate grade) within the excised sample.
On review of the pathology, the multidisciplinary team (MDT)
recommended a right axillary sentinel lymph node biopsy due to
the presence of mixed invasive lobular carcinoma and DCIS. The
two sentinel lymph nodes biopsied demonstrated no evidence of
malignancy.
Post-operatively, the patient received adjuvant radiotherapy to
both breasts and adjuvant Tamoxifen 20mg daily, in consideration
of the hormone status on her lobular carcinoma of the right breast.
At 2 years follow-up, the patient is well with no evidence of recur-
rence.
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Table 1
Summary of previously reported cases of phyllodes tumours with heterogenic sarcomatous differentiation.
Authors Year Age Site Size (cm) Treatment Final pathology Follow up
Tomas et al. [5] 2007 71 R 3.3 Mastectomy, axillary
dissection and
chemotherapy
Malignant phyllodes with
osteo/chondro/liposarcomatous
differentiation
1 year: disease free
Guerrero et al. [6] 2003 96 L 17×13×8 Wide local excision Malignant phyllodes with
lipo/ﬁbro/rhabdo/
leiomyosarcomatous
differentiation
10 months: dead, due to
pneumonia
Garcia et al. [8] 1999 51 L 5×4.5×3 Mastectomy, axillary
dissection
Malignant phyllodes with
chondro/osteosarcomatous and
MFH differentiation
16 months: disease free
De Luca et al. [7] 1986 41 L 30×24×20 Mastectomy,
chemotherapy
Malignant phyllodes with
lipo/ﬁbrosarcomatous, anaplastic
and giant cell differentiation
4 months: dead with
pulmonary metastases
2.2. Case 2
A 53 year old female presented with a painful, palpable lump in
the upper outer quadrant of her left breast. She had a ﬁbroadenoma
excised from her left breast in 1995 and regularly attended breast
screening for persisting breast cysts. On examination, there was
a ﬁrm 3cm mass in the upper outer quadrant of her left breast,
just proximal to the scar that was made during the excision of
her ﬁbroadenoma. Ultrasound revealed a solid mass measuring
3.3×2.5 cm with a heterogeneous echo pattern, cystic spaces and
well-deﬁned margins.
A core biopsy demonstrated the lesion to be a PT and the patient
underwent a wide local excision (WLE) of her left breast lesion.
Pathology revealed a malignant PT measuring 2.5×3.3 cm with
stromal cellularity varying from mild to sarcomatous, with both
osteosarcoma and liposarcoma contained within the PT. In these
areas, the mitotic rate was borderline (8per 10 high power ﬁelds).
The margins for PT were not clear at the anterior and inferior mar-
gins.
The patient considered a repeatWLEor amastectomy andopted
for theWLE. She underwent an upper outer quadrantectomy of her
left breast, with no operative complications. The pathology from
this excision demonstrated clearmargins and she is currently being
followedup6monthly. At 2years follow-up, thepatient iswellwith
no evidence of recurrence.
Fig. 4. (H&E): phyllodes tumour with malignant chondrosarcoma.
3. Discussion
Phyllodes tumours, ﬁrst described as Cytosarcoma phyllodes by
Muller in 1838 [9], display a wide range of clinical, histological
and cytological features [3,4]. Based on histological and cytolog-
ical ﬁndings, PTs are classiﬁed as benign, borderline or malignant.
This classiﬁcation allows for the interpretation of PTs as a contin-
uum of the spectrum of ﬁbroepithelial neoplasms of breast tissue;
benign PTs can be difﬁcult to distinguish fromﬁbroadenomaswhile
malignant PTs can grow in size quickly and metastasise early [3].
Microscopically, PTs are characterised by a leaf-like appearance,
created by projections of hypercellular stroma into epithelium-
lined cystic spaces. The presence of dual population of both
epithelial and stromal cells is necessary for the diagnosis of PT
[9]. However, the characteristic histological features are related to
the stroma [3] and PTs are differentiated from ﬁbroadenomas by
marked stromal overgrowth and hypercellularity [3].
There are numerous histological grading systems for PTs, with
multiple revisions of the classiﬁcation ﬁrst described by Treves
and Sutherland in 1951 [10]. Most grading systems are 3-tiered:
“benign, borderline or malignant” or “low, intermediate or high
grade” and use the same histological parameters (with varying cut-
offs): margins characteristics, cellular atypia, stromal overgrowth,
stromal cellularity, and mitotic rate [3].
A variety of associated malignancies can arise from PTs, with
its dual population of cells [6]. The stromal cells can demonstrate
sarcomatous differentiation while the epithelial component can
become malignant with DCIS/LCIS or invasive carcinoma. There
have also been case reports of two distinctly separate lesions of
PT and primary sarcoma or PT and carcinoma [11,12].
The two cases discussed above demonstrate sarcomatous dif-
ferentiation of the stromal cells in malignant PT, with further
development of epithelial malignancy (DCIS) in the ﬁrst case. The
ﬁrst case is also unique in that this was associated with a con-
tralateral lobular carcinoma and DCIS. It is very unusual to note
heterologous sarcomatous differentiation in PTs and Table 1 sum-
marises the 4 previous cases of such heterogeneity in English
literature, all of which arose out of malignant PTs.
There is a paucity of evidence regarding surgical and adjuvant
therapy and rates of local control makes it difﬁcult to recommend
a speciﬁc treatment for patients [6,13]. In isolated PTs, wide local
excision with margins of 1 cm is recommended with minimal evi-
dence for chemotherapy or hormone therapy [4], and this was
the treatment of choice of case 2, who continues to have close
post-operativemonitoring. However, some authors suggest the use
of adjuvant therapy in PTs greater than 5 cm with more than 20
mitoses per 10 high power ﬁelds as these tumours may have a
higher local recurrence rate [13], and hence adjuvant radiotherapy
was offered in case 1.
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The prognosis of PTs is poorly deﬁned, with local recurrence
rates ranging from 10 to 40% (average 15%) and distant metas-
tases occurring in 10% of all phyllodes tumours, and up to 20% of
malignant phyllodes tumours [3]. Survival after metastatic disease
is poor,with case series reportingmedian survival ranging from4 to
17 months [4]. However, these ﬁgures vary from one case series to
another, with Reinfuss et al. reporting 5 year disease-free survival
rates of 96% in benign phyllodes tumours and 66% in malignant
phyllodes tumours [14] In the 4 case reports of malignant phyl-
lodes tumourswith heterologous sarcomatous differentiation, only
1 patient had disease-related death at 4 months [7], while another
was disease-free at 16 months [8].
In summary, we present two extremely rare cases of malignant
PT with heterologous sarcomatous differentiation, and note that
further research is required to develop management guidelines for
highly malignant PTs.
4. Learning points
1. Phyllodes tumours with heterologous sarcomatous differen-
tiation are extremely rare.
2. There is limited literature to guide adjuvant therapy and
prognosis for phyllodes tumours with heterologous sarcomatous
differentiation.
5. Patient consent
Written informed consent was obtained from the patients for
publication of this case report and accompanying images. A copy
of thewritten consent is available for review by the Editor-in-Chief
of this journal on request.
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